Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.

A. Borley, T. Mercer, M. Morgan, P. Dutton, P. Barrett-Lee, M. Brunelli, B. Jasani

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Adjuvant trastuzumab with chemotherapy is standard treatment for HER2-positive breast cancer, defined as either HER2 IHC3+ or IHC2+ and FISH amplified. The aim of this study was to investigate the degree to which HER2 amplification in terms of HER2 gene copy numbers in HER2+IHC2+ cancers affected the outcome in a community setting. Case records of 311 consecutive patients with early breast cancer presenting between 1st January 2005 and 31st December 2008 were reviewed. Progression-free survival and overall survival were calculated with the Kaplan-Meier method using STATA 13. Among 3+ cases (n=230) 163 received T vs 67 no-T. Among 2+ cases (n=81) 59 received T vs 22 no-T. Among 59 IHC2+-treated cases n=28 had an average of >12, n=13 had >6 to 2 to 12) appears to be associated with consistently better response compared with patients with intermediate HER2 copy numbers (6-12). In light of emerging data of patients showing insensivity to trastuzumab therapy, we propose that the HER2 gene copy number value should be included as an additional indicator for stratifying both the management and the follow-up of breast cancer patients.

Original languageEnglish
Pages (from-to)2139-2143
Number of pages5
JournalBritish Journal of Cancer
Volume110
Issue number8
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Breast Neoplasms
erbB-2 Genes
Gene Dosage
Neoplasms
Therapeutics
Disease-Free Survival
Drug Therapy
Survival
Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network. / Borley, A.; Mercer, T.; Morgan, M.; Dutton, P.; Barrett-Lee, P.; Brunelli, M.; Jasani, B.

In: British Journal of Cancer, Vol. 110, No. 8, 2014, p. 2139-2143.

Research output: Contribution to journalArticle

Borley, A. ; Mercer, T. ; Morgan, M. ; Dutton, P. ; Barrett-Lee, P. ; Brunelli, M. ; Jasani, B. / Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network. In: British Journal of Cancer. 2014 ; Vol. 110, No. 8. pp. 2139-2143.
@article{f64b9d3dc1434ada9cd7722915387d7b,
title = "Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.",
abstract = "Adjuvant trastuzumab with chemotherapy is standard treatment for HER2-positive breast cancer, defined as either HER2 IHC3+ or IHC2+ and FISH amplified. The aim of this study was to investigate the degree to which HER2 amplification in terms of HER2 gene copy numbers in HER2+IHC2+ cancers affected the outcome in a community setting. Case records of 311 consecutive patients with early breast cancer presenting between 1st January 2005 and 31st December 2008 were reviewed. Progression-free survival and overall survival were calculated with the Kaplan-Meier method using STATA 13. Among 3+ cases (n=230) 163 received T vs 67 no-T. Among 2+ cases (n=81) 59 received T vs 22 no-T. Among 59 IHC2+-treated cases n=28 had an average of >12, n=13 had >6 to 2 to 12) appears to be associated with consistently better response compared with patients with intermediate HER2 copy numbers (6-12). In light of emerging data of patients showing insensivity to trastuzumab therapy, we propose that the HER2 gene copy number value should be included as an additional indicator for stratifying both the management and the follow-up of breast cancer patients.",
author = "A. Borley and T. Mercer and M. Morgan and P. Dutton and P. Barrett-Lee and M. Brunelli and B. Jasani",
year = "2014",
doi = "10.1038/bjc.2014.147",
language = "English",
volume = "110",
pages = "2139--2143",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.

AU - Borley, A.

AU - Mercer, T.

AU - Morgan, M.

AU - Dutton, P.

AU - Barrett-Lee, P.

AU - Brunelli, M.

AU - Jasani, B.

PY - 2014

Y1 - 2014

N2 - Adjuvant trastuzumab with chemotherapy is standard treatment for HER2-positive breast cancer, defined as either HER2 IHC3+ or IHC2+ and FISH amplified. The aim of this study was to investigate the degree to which HER2 amplification in terms of HER2 gene copy numbers in HER2+IHC2+ cancers affected the outcome in a community setting. Case records of 311 consecutive patients with early breast cancer presenting between 1st January 2005 and 31st December 2008 were reviewed. Progression-free survival and overall survival were calculated with the Kaplan-Meier method using STATA 13. Among 3+ cases (n=230) 163 received T vs 67 no-T. Among 2+ cases (n=81) 59 received T vs 22 no-T. Among 59 IHC2+-treated cases n=28 had an average of >12, n=13 had >6 to 2 to 12) appears to be associated with consistently better response compared with patients with intermediate HER2 copy numbers (6-12). In light of emerging data of patients showing insensivity to trastuzumab therapy, we propose that the HER2 gene copy number value should be included as an additional indicator for stratifying both the management and the follow-up of breast cancer patients.

AB - Adjuvant trastuzumab with chemotherapy is standard treatment for HER2-positive breast cancer, defined as either HER2 IHC3+ or IHC2+ and FISH amplified. The aim of this study was to investigate the degree to which HER2 amplification in terms of HER2 gene copy numbers in HER2+IHC2+ cancers affected the outcome in a community setting. Case records of 311 consecutive patients with early breast cancer presenting between 1st January 2005 and 31st December 2008 were reviewed. Progression-free survival and overall survival were calculated with the Kaplan-Meier method using STATA 13. Among 3+ cases (n=230) 163 received T vs 67 no-T. Among 2+ cases (n=81) 59 received T vs 22 no-T. Among 59 IHC2+-treated cases n=28 had an average of >12, n=13 had >6 to 2 to 12) appears to be associated with consistently better response compared with patients with intermediate HER2 copy numbers (6-12). In light of emerging data of patients showing insensivity to trastuzumab therapy, we propose that the HER2 gene copy number value should be included as an additional indicator for stratifying both the management and the follow-up of breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84901836486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901836486&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.147

DO - 10.1038/bjc.2014.147

M3 - Article

VL - 110

SP - 2139

EP - 2143

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -